Search Results

You are looking at 101 - 110 of 165 items for :

  • "early breast cancer" x
  • All content x
Clear All
Full access

Komal Jhaveri and Francisco J. Esteva

plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) . Ann Oncol

Full access

NCCN Guidelines Insights: Breast Cancer, Version 3.2018

Featured Updates to the NCCN Guidelines

Matthew P. Goetz, William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, William B. Farrar, Sharon H. Giordano, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Meena S. Moran, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Melinda L. Telli, John H. Ward, Jessica S. Young, Dorothy A. Shead, and Rashmi Kumar

use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. Breast Cancer Res Treat 2017 ; 165 : 573 – 583 . 11

Full access

Benjamin L. Franc, Timothy P. Copeland, Robert Thombley, Miran Park, Ben Marafino, Mitzi L. Dean, W. John Boscardin, Hope S. Rugo, David Seidenwurm, Bhupinder Sharma, Stephen R. Johnston, and R. Adams Dudley

appropriate follow-up of primary breast cancer patients . J Clin Oncol 1994 ; 12 : 1996 – 1997 . 12. Rojas MP Telaro E Russo A . Follow-up strategies for women treated for early breast cancer . Cochrane Database Syst Rev 2000 : CD001768

Full access

Yanli Li, Leila Family, Su-Jau Yang, Zandra Klippel, John H. Page, and Chun Chao

. Docetaxel and cyclophosphamide as adjuvant chemotherapy for early breast cancer: primary prophylaxis with G-CSF is required . Breast Cancer Manag 2013 ; 2 : 367 – 374 . 11. Younis T Rayson D Thompson K . Primary G-CSF prophylaxis for adjuvant

Full access

Davinia S.E. Seah, Ines Vaz Luis, Erin Macrae, Jessica Sohl, Georgia Litsas, Eric P. Winer, Nancy U. Lin, and Harold J. Burstein

cancer. Monoclonal antibodies and tyrosine kinase inhibitors . Breast 2013 ; 22 : 1 – 12 . 16. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) , Peto R Davies C . Comparisons between different polychemotherapy regimens for

Full access

Suzanne C. O'Neill, Claudine Isaacs, Calvin Chao, Huei-Ting Tsai, Chunfu Liu, Bola F. Ekezue, Nandini Selvam, Larry G. Kessler, Marc D. Schwartz, Tania Lobo, and Arnold L. Potosky

does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. References 1. Goldhirsch A Winer EP Coates AS . Personalizing the treatment of women with early breast cancer

Full access

Gary H. Lyman and David C. Dale

controlled trials of adjuvant chemotherapy in 7110 patients with early breast cancer treated with epirubicin, most of whom also received cyclophosphamide, reported a cumulative probability of AML/MDS out to 8 years of 0.55% (95% CI, 0.33%–0.78%). 13 The risk

Full access

NCCN Guidelines® Insights: Breast Cancer, Version 4.2021

Featured Updates to the NCCN Guidelines

William J. Gradishar, Meena S. Moran, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Sara A. Hurvitz, Steven J. Isakoff, Rachel C. Jankowitz, Sara H. Javid, Jairam Krishnamurthy, Marilyn Leitch, Janice Lyons, Jennifer Matro, Ingrid A. Mayer, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Kari B. Wisinski, Jessica S. Young, Jennifer L. Burns, and Rashmi Kumar

early breast cancer; results of the IDEAL trial (BOOG 2006-05) . J Natl Cancer Inst 2018 ; 110 : 110 . 16. Noordhoek I , Treuner K , Putter H , Breast cancer index predicts extended endocrine benefit to individualize selection of patients

Full access

Cynthia Villarreal-Garza, Fernanda Mesa-Chavez, Alejandra Plata de la Mora, Melina Miaja-Avila, Marisol Garcia-Garcia, Alan Fonseca, Sylvia de la Rosa-Pacheco, Marlid Cruz-Ramos, Manuel Rolando García Garza, Alejandro Mohar, and Enrique Bargallo-Rocha

– 2129 . 34. Ter Welle-Butalid MEE , Vriens IJHI , Derhaag JGJ , et al. Counseling young women with early breast cancer on fertility preservation . J Assist Reprod Genet 2019 ; 36 : 2593 – 2604 . 35. Lambertini M , Fontanella C

Full access

Therese B. Bevers, Deborah K. Armstrong, Banu Arun, Robert W. Carlson, Kenneth H. Cowan, Mary B. Daly, Irvin Fleming, Judy E. Garber, Mary Gemignani, William J. Gradishar, Helen Krontiras, Swati Kulkarni, Christine Laronga, Loretta Loftus, Deborah J. MacDonald, Martin C. Mahoney, Sofia D. Merajver, Ingrid Meszoely, Lisa Newman, Elizabeth Pritchard, Victoria Seewaldt, Rena V. Sellin, Charles L. Shapiro, and John H. Ward

pregnancy potential without effective method of contraception, and known inherited clotting trait. The optimal duration of SERM therapy for breast cancer risk reduction is not known. In the Early Breast Cancer Trialists' most recent overview analysis